| |
DOG Congress Home
Program Changes
Registration
Invitations
Organization, Deadlines
Overview of the Congress
Scientific Programme
Scientific Programme
Highlights
Symposia
Courses
Satellite Programme
Information
Social Programme
Sponsors, Exhibitors
For the Press
DOG Homepage
|
|
AbstractDO.05.01 Fluorescenceangiography of Knock-out mice for Nucleotid-related factor E2 related factor (Nrf2) and on diabetic mice Koinzer S.1, Klettner A.1, Alten F.1, Treumer F.1, v. Wurmb-Schwark N.2, Wruck C.3, Roider J.1 1Klinik für Ophthalmologie, 2Institut für Rechtsmedizin, Universitätsklinikum-Schleswig-Holstein, Campus Kiel, 3Anatomisches Institut, Christian Albrechts Universität, Kiel Objective: Nucleotid-related factor E2 related factor (Nrf2) is a trigger protein for the translational cellular response to oxidative stress. Nrf2 is considered a multi-organ protector. To examine the in vivo effect of Nrf2 deficiency on retinal vessels, fluorescence angiography was perfomed on 1 and 6 month old Nrf2-knock out mice. Wild type mice and diabetic mice served as controls. Methods: 6 mice in each group were examined by fluorescence angiography. Streptozotozin was used to induce experimental diabetes mellitus. Results: Nrf2 knock out mice did not develop diabetes like wild type mice. In none of the mice leakage or exsudation was detected. Nrf2-KO mice presented slight focal ectasia on first order vessels. Diabetic mice presented slightly irregular diameters of first order vessels. Neither group of mice showed significant changes of the capillary network at any time examined. Conclusions: Diabetic wild type mice were at pathological oxidative stress exposition, but at regular oxidative stress defence. Nrf2-KO mice were exposed to physiological oxidative stress at dimished oxidative stress defence. Both groups had distinct vessel changes in fluoresecence angiography. Diabetic changes differed from the known changes in diabetic mouse retina, which were studied on specimens and showed capillary changes after more than one year duration of diabetes. Nrf2 might be a possible effector for anti-angiogenic therapy.
|
|